|
EP0711804A3
(de)
|
1994-11-14 |
1999-09-22 |
Ciba SC Holding AG |
Kryptolichtschutzmittel
|
|
JP3512911B2
(ja)
|
1995-07-11 |
2004-03-31 |
富士写真フイルム株式会社 |
紫外線吸収剤前駆体化合物、それを含有する感光性樹脂組成物及び画像形成方法
|
|
DK1020462T3
(da)
|
1997-07-24 |
2004-04-26 |
Zenyaku Kogyo Kk |
Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens
|
|
JPH11174638A
(ja)
|
1997-12-08 |
1999-07-02 |
Konica Corp |
ハロゲン化銀カラー写真感光材料
|
|
US6777439B2
(en)
|
2000-05-30 |
2004-08-17 |
Advanced Research & Technology Institute, Inc. |
Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
|
|
JP3836436B2
(ja)
|
2001-04-27 |
2006-10-25 |
全薬工業株式会社 |
複素環式化合物及びそれを有効成分とする抗腫瘍剤
|
|
DE10207037A1
(de)
|
2002-02-20 |
2003-08-28 |
Bayer Cropscience Gmbh |
2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
|
|
ATE468336T1
(de)
|
2002-03-15 |
2010-06-15 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
ATE433973T1
(de)
|
2002-03-15 |
2009-07-15 |
Vertex Pharma |
Azolylaminoazine als inhibitoren von proteinkinasen
|
|
EP1485100B1
(en)
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles as inhibitors of protein kinases
|
|
ES2289279T3
(es)
|
2002-03-15 |
2008-02-01 |
Vertex Pharmaceuticals Incorporated |
Composiciones utiles como inhibidores de proteinquinasas.
|
|
KR20040111636A
(ko)
|
2002-05-17 |
2004-12-31 |
교와 핫꼬 고교 가부시끼가이샤 |
항당뇨병 작용을 갖는 물질의 탐색방법
|
|
DK1557415T3
(da)
|
2002-10-25 |
2012-09-17 |
Zenyaku Kogyo Kk |
Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
|
|
ES2412273T3
(es)
|
2002-11-21 |
2013-07-10 |
Novartis Ag |
Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
|
|
WO2005028467A1
(en)
|
2003-09-15 |
2005-03-31 |
Anadys Pharmaceuticals, Inc. |
Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
|
|
DK1704145T3
(da)
|
2004-01-12 |
2012-09-24 |
Ym Biosciences Australia Pty |
Selektive kinaseinhibitorer
|
|
US7855199B2
(en)
|
2004-03-31 |
2010-12-21 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
|
|
NZ552946A
(en)
|
2004-08-26 |
2010-09-30 |
Pfizer |
Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
|
|
WO2006053109A1
(en)
|
2004-11-10 |
2006-05-18 |
Synta Pharmaceuticals Corp. |
Heteroaryl compounds
|
|
TW200628159A
(en)
|
2004-11-10 |
2006-08-16 |
Synta Pharmaceuticals Corp |
IL-12 modulatory compounds
|
|
TWI381841B
(zh)
|
2005-03-11 |
2013-01-11 |
Zenyaku Kogyo Kk |
An immunosuppressive agent and an antitumor agent containing a heterocyclic compound as an active ingredient
|
|
GB0525081D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US20070244110A1
(en)
|
2006-04-14 |
2007-10-18 |
Zenyaku Kogyo Kabushiki Kaisha |
Treatment of prostate cancer, melanoma or hepatic cancer
|
|
PL2041139T3
(pl)
|
2006-04-26 |
2012-05-31 |
Hoffmann La Roche |
Związki farmaceutyczne
|
|
MX2008013583A
(es)
|
2006-04-26 |
2008-10-31 |
Genentech Inc |
Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
|
|
BRPI0714908B8
(pt)
|
2006-08-08 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
|
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032086A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
US20090270390A1
(en)
|
2006-09-14 |
2009-10-29 |
Astrazeneca |
Pyrimidine derivatives
|
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032041A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives having inhibitory activity against pi3k enzymes
|
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
EP2064203A1
(en)
|
2006-09-14 |
2009-06-03 |
AstraZeneca AB |
2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JP2010503648A
(ja)
|
2006-09-14 |
2010-02-04 |
アストラゼネカ アクチボラグ |
増殖性疾患の治療のためのｐｉ３ｋ及びｍｔｏｒ阻害剤としての２−ベンゾイミダゾリル−６−モルホリノ−４−（アゼチジン、ピロリジン、ピペリジン、又はアゼピン）ピリミジン誘導体
|
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
ES2381895T3
(es)
|
2007-02-06 |
2012-06-01 |
Novartis Ag |
Inhibidores de PI 3-quinasa y métodos para su uso
|
|
WO2008110891A2
(en)
|
2007-03-09 |
2008-09-18 |
Orchid Research Laboratories Limited, |
New heterocyclic compounds
|
|
US20080233127A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
|
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
|
JP2010529193A
(ja)
|
2007-06-11 |
2010-08-26 |
ミイカナ セラピューティクス インコーポレイテッド |
置換ピラゾール化合物
|
|
US20100227858A1
(en)
|
2007-07-09 |
2010-09-09 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
CN104119336B
(zh)
|
2007-10-05 |
2016-08-24 |
维拉斯通股份有限公司 |
嘧啶取代的嘌呤衍生物
|
|
WO2009045174A1
(en)
|
2007-10-05 |
2009-04-09 |
S*Bio Pte Ltd |
2-morpholinylpurines as inhibitors of pi3k
|
|
WO2009066775A1
(ja)
|
2007-11-22 |
2009-05-28 |
Zenyaku Kogyo Kabushikikaisha |
複素環式化合物の非晶質体、それを含む固体分散体、薬剤、およびその製造法
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
CN102014914A
(zh)
|
2008-01-15 |
2011-04-13 |
惠氏有限责任公司 |
3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
|
|
WO2009093981A1
(en)
|
2008-01-23 |
2009-07-30 |
S Bio Pte Ltd |
Triazine compounds as kinase inhibitors
|
|
US20090192176A1
(en)
|
2008-01-30 |
2009-07-30 |
Wyeth |
1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
|
|
TW200938201A
(en)
|
2008-02-07 |
2009-09-16 |
Chugai Pharmaceutical Co Ltd |
Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
|
|
US20110053907A1
(en)
|
2008-03-27 |
2011-03-03 |
Auckland Uniservices Limited |
Substituted pyrimidines and triazines and their use in cancer therapy
|
|
EA020317B1
(ru)
|
2008-05-23 |
2014-10-30 |
УАЙТ ЭлЭлСи |
ТРИАЗИНЫ КАК ИНГИБИТОРЫ КИНАЗЫ PI3 И mTOR
|
|
US20110105500A1
(en)
|
2008-06-27 |
2011-05-05 |
S*Bio Pte Ltd. |
Pyrazine substituted purines
|
|
CA2730271A1
(en)
|
2008-07-07 |
2010-01-14 |
Xcovery Holding Company Llc |
Pi3k isoform selective inhibitors
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
|
NZ631024A
(en)
|
2008-11-13 |
2016-04-29 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
KR20110120286A
(ko)
|
2009-02-12 |
2011-11-03 |
아스텔라스세이야쿠 가부시키가이샤 |
헤테로환 유도체
|
|
US8461158B2
(en)
*
|
2009-03-27 |
2013-06-11 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
US8173650B2
(en)
|
2009-05-27 |
2012-05-08 |
Genentech, Inc. |
Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
|
|
WO2010136491A1
(en)
|
2009-05-27 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
|
|
MX2011013666A
(es)
|
2009-06-25 |
2012-03-06 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
|
US8754089B2
(en)
|
2009-06-25 |
2014-06-17 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
|
JP2012531436A
(ja)
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
|
|
UY32743A
(es)
|
2009-06-25 |
2010-12-31 |
Amgen Inc |
Compuestos heterocíclicos y sus usos
|
|
US8486939B2
(en)
*
|
2009-07-07 |
2013-07-16 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
CN103025725B
(zh)
|
2010-08-10 |
2015-09-16 |
安斯泰来制药有限公司 |
杂环化合物
|
|
AU2011338530B2
(en)
|
2010-12-06 |
2017-06-15 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
|
WO2012096417A1
(en)
*
|
2011-01-11 |
2012-07-19 |
Inha Industry Partnership Institute |
Audio signal quality measurement in mobile device
|
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
CA2831582C
(en)
*
|
2011-03-28 |
2019-01-08 |
Mei Pharma, Inc. |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
BR112013024909A2
(pt)
|
2011-03-28 |
2019-09-24 |
Mei Pharma Inc |
composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
|
|
EP2691388A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
EP2723747A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
WO2012178123A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013006408A1
(en)
|
2011-07-01 |
2013-01-10 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
|
US9499474B2
(en)
|
2011-11-11 |
2016-11-22 |
Merck Patent Gmbh |
Process for producing arylamines
|
|
JP6347782B2
(ja)
|
2012-08-09 |
2018-06-27 |
セルジーン コーポレイション |
３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
WO2014141129A2
(en)
|
2013-03-14 |
2014-09-18 |
Grueneberg Dorre A |
Novel methods, compounds, and compositions for inhibition of ros
|
|
EP2832358A1
(en)
|
2013-08-02 |
2015-02-04 |
Bionsil S.r.l. |
Pharmaceutical kit for use in the treatment of colon and colorectal cancer
|
|
AU2014358868A1
(en)
|
2013-12-05 |
2016-06-09 |
Acerta Pharma B.V. |
Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
|
|
US10227360B2
(en)
|
2014-02-19 |
2019-03-12 |
Piramal Enterprises Limited |
Compounds for use as GPR120 agonists
|
|
WO2015193740A2
(en)
|
2014-06-17 |
2015-12-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
|
|
WO2016010879A1
(en)
*
|
2014-07-15 |
2016-01-21 |
The Johns Hopkins University |
Suppression of myeloid derived suppressor cells and immune checkpoint blockade
|
|
SI3179992T1
(sl)
*
|
2014-08-11 |
2022-09-30 |
Acerta Pharma B.V. |
Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
|
|
TW201618774A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
CA2970011C
(en)
|
2014-12-24 |
2021-08-03 |
Lg Chem, Ltd. |
Biaryl derivative as gpr120 agonist
|
|
SG10201912699RA
(en)
|
2015-07-20 |
2020-02-27 |
Genzyme Corp |
Colony stimulating factor-1 receptor (csf-1r) inhibitors
|
|
CN105130960B
(zh)
*
|
2015-07-31 |
2018-07-06 |
沈阳药科大学 |
1,3,5-三嗪类衍生物及其应用
|
|
MX2018002344A
(es)
|
2015-08-24 |
2018-07-06 |
Epizyme Inc |
Metodo para tratar el cancer.
|
|
TW201725044A
(zh)
*
|
2015-10-01 |
2017-07-16 |
基利科學股份有限公司 |
用於治療癌症之btk抑制劑及查核點抑制劑之組合
|
|
CA3001857A1
(en)
|
2015-10-14 |
2017-04-20 |
Aquinnah Pharmaceuticals, Inc. |
Compounds, compositions and methods of use against stress granules
|
|
CN116769050A
(zh)
|
2016-07-20 |
2023-09-19 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
|
JP2019529419A
(ja)
|
2016-09-19 |
2019-10-17 |
エムイーアイ ファーマ，インク． |
併用療法
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
CA3063976A1
(en)
*
|
2017-05-23 |
2018-11-29 |
Mei Pharma, Inc. |
Combination therapy
|
|
MX2020001727A
(es)
|
2017-08-14 |
2020-03-20 |
Mei Pharma Inc |
Terapia de combinacion.
|
|
MA52090A
(fr)
|
2018-03-21 |
2021-04-21 |
Mei Pharma Inc |
Polythérapie
|
|
AU2019322858A1
(en)
|
2018-08-14 |
2021-04-01 |
Mei Pharma, Inc. |
Combination therapy
|
|
WO2020036999A1
(en)
|
2018-08-14 |
2020-02-20 |
Mei Pharma, Inc. |
Treatment of b cell malignancies
|
|
MX2021001765A
(es)
|
2018-08-14 |
2021-04-19 |
Mei Pharma Inc |
Tratamiento del linfoma follicular reicindido.
|
|
WO2020132563A1
(en)
|
2018-12-21 |
2020-06-25 |
Mei Pharma, Inc. |
Combination therapy
|